



WHAT IS CLAIMED IS:

1. A compound of formula I'




5

wherein each of A¹ and A² is independently C or N;
 wherein A¹-A² form part of a ring A selected from 5- or 6-
 membered heteroaryl;



- 10 wherein X is
 wherein Z is oxygen or sulfur;

Y is selected from



15

wherein p is 0 to 2,

wherein R² is selected from C₂-C₆-alkylenyl, where one of the CH₂ groups may be replaced with an oxygen atom or an -NH-group; wherein one of the CH₂ groups may be substituted with one or two radicals selected from halo, cyano, -NHR⁶ and C₁₋₄-alkyl substituted with R¹;

10 wherein R¹ is one or more substituents independently
selected from H, halo, -OR⁷, oxo, -SR⁷, -CO₂R⁷, -COR⁷,
-CONR⁷R⁷, -NR⁷R⁷, -SO₂NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷,
optionally substituted cycloalkyl, optionally substituted
phenylalkyl, optionally substituted heterocyclcyl,
15 optionally substituted heterocyclcylalkyl, optionally
substituted phenyl, lower alkyl, cyano, lower
hydroxyalkyl, lower carboxyalkyl, nitro, lower alkenyl,
lower alkynyl, lower aminoalkyl, lower alkylaminoalkyl
and lower haloalkyl;

20 wherein R² is selected from

- a) substituted or unsubstituted 6-10 membered aryl,
- b) substituted or unsubstituted 5-6 membered heterocyclyl,
- c) substituted or unsubstituted 9-14 membered bicyclic or
- 25 tricyclic heterocyclyl,
- d) cycloalkyl, and
- e) cycloalkenyl,

wherein substituted R² is substituted with one or more substituents independently selected from halo, -OR⁷, oxo, -SR⁷, -CO₂R⁷, -CONR⁷R⁷, -COR⁷, -NR⁷R⁷, -NH(C₁-C₄ alkylenylR⁹), -SO₂R⁷, -SO₂NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, -NR⁷C(O)NR⁷R⁷, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted phenyl, halosulfonyl, cyano,

alkylaminoalkoxy, alkylaminoalkoxyalkoxy, nitro, lower alkyl substituted with R^1 , lower alkenyl substituted with R^1 , and lower alkynyl substituted with R^1 ;
wherein R^3 is selected from aryl unsubstituted or
5 substituted with one or more substituents independently selected from halo, $-OR^7$, $-SR^7$, $-SO_2R^7$, $-CO_2R^7$, $-CONR^7R^7$, $-COR^7$, $-NR^7R^7$, $-SO_2NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted phenyl, nitro,
10 alkylaminoalkoxyalkoxy, cyano, alkylaminoalkoxy, lower alkyl substituted with R^1 , lower alkenyl substituted with R^1 , and lower alkynyl substituted with R^1 ;
wherein R^4 is selected from a direct bond, C_{2-4} -alkylenyl, C_{2-4} -alkenylenyl and C_{2-4} -alkynylenyl, where one of the CH_2
15 groups may be substituted with an oxygen atom or an $-NH-$, wherein R^4 is optionally substituted with hydroxy;
wherein R^5 is selected from H, lower alkyl, optionally substituted phenyl and lower aralkyl;
wherein R^{5a} is selected from H, lower alkyl, optionally
20 substituted phenyl and lower aralkyl;
wherein R^6 is selected from H or C_{1-6} -alkyl; and
wherein R^7 is selected from H, lower alkyl, optionally substituted phenyl, optionally substituted heterocyclyl, optionally substituted C_3-C_6 -cycloalkyl, optionally
25 substituted phenyl- C_{1-6} -alkyl, optionally substituted heterocyclyl- C_{1-6} -alkyl, optionally substituted C_3-C_6 cycloalkyl- C_{1-6} -alkyl, alkylaminoalkyl, and lower haloalkyl;
wherein R^9 is selected from H, optionally substituted
30 phenyl, optionally substituted 5-6 membered heterocyclyl and optionally substituted C_3-C_6 cycloalkyl;
and pharmaceutically acceptable derivatives thereof;
provided R^2 is not 3-trifluoromethylphenyl when A is pyridyl, when X is $-C(O)NH-$, when Y is $-NH-CH_2-$, when

Sub
B1

"E04B005000"

R¹ is H and R³ is 3-(N-methylamino-carbonyl)phenyl, 4-hydroxyphenyl, 3-hydroxyphenyl or phenyl;
further provided R² is not substituted with -SO₂NR⁷R⁷ when Y is -NHSO₂-;

5 further provided R² is not 3-trifluoromethylphenyl when A is pyridyl, when X is -C(O)NH-, when Y is -N(benzyl)-CH₂-, when R¹ is H and when R³ is phenyl;

Sub
H¹
10 further provided R² is not cyclohexyl when A is pyridyl, when X is -C(O)NH-, when Y is -NH-CH₂-, when R¹ is H and when R³ is 2-methoxyphenyl or 3-methoxyphenyl;
further provided R¹ is not 2-hydroxymethylpyrrol-5-yl when A is pyridyl;

further provided R¹ is not 4-(methoxyaminocarbonylamino)phenyl when A is thienyl;


15 further provided R¹ is not 2-pyridylmethoxy when A is pyrimidyl, when X is -C(O)NH-, and when Y is -NH-CH₂-;
further provided R¹ is not 4-methylpiperidyl when A is pyrimidyl, when X is -C(O)NH-, when Y is -NH-CH₂-, and when R³ is 3-chloro-4-methoxyphenyl;

20 further provided R¹ is not bromo when A is pyrimidyl, when X is -C(O)NH-CH₂-, when Y is -NH-CH₂-, and when R³ is 3-chloro-4-methoxyphenyl;


further provided R² is not 2-chloro-3-pyridyl when A is pyridyl; and

25 further provided R² is not 2-methoxyphenyl when A is pyridyl, when X is -C(O)NH-, when Y is -NH-CH₂-, when R¹ is H and R³ is phenyl.

2. Compound of Claim 1 wherein A is selected from
30 thienyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, triazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl; wherein X is selected from



wherein Y is selected from




- 5 wherein R^a and R^b are independently selected from H, halo, and C_{1-2} -alkyl substituted with R^1 , or wherein R^a and R^b together form $\text{C}_3\text{-C}_4$ cycloalkyl; wherein R^z is $\text{C}_2\text{-C}_3$ alkylene, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH- ;
- 10 wherein R^1 is one or more substituents independently selected from H, halo, -OR^7 , oxo, -SR^7 , $\text{-CO}_2\text{R}^7$, $\text{-CONR}^7\text{R}^7$, -COR^7 , $\text{-NR}^7\text{R}^7$, $\text{-SO}_2\text{NR}^7\text{R}^7$, $\text{-NR}^7\text{C}(\text{O})\text{OR}^7$, $\text{-NR}^7\text{C}(\text{O})\text{R}^7$, optionally substituted C_{3-6} -cycloalkyl, optionally substituted phenyl- C_{1-4} -alkyl, optionally substituted 4-6 membered
- 15 heterocyclyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkyl, C_{1-6} -alkyl, cyano, C_{1-4} -hydroxyalkyl, C_{1-4} -carboxyalkyl, nitro, C_{2-3} -alkenyl, C_{2-3} -alkynyl and C_{1-4} -haloalkyl; wherein R^2 is selected from
- 20 substituted or unsubstituted aryl selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, substituted or unsubstituted C_{3-6} -cycloalkyl and substituted or unsubstituted 9-10 membered bicyclic or
- 25 13-14 membered tricyclic saturated or partially unsaturated heterocyclyl wherein substituted R^2 is substituted with one or more substituents independently selected from halo, -OR^7 , oxo,

Sub
B1

EQUATE 340000

-SR⁷, -SO₂R⁷, -CO₂R⁷, -CONR⁷R⁷, -COR⁷, -NR⁷R⁷, -NH(C₁-C₂-alkylenylR⁹), -(C₁-C₂-alkylenyl)NR⁷R⁷, -SO₂NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, C₁-C₆-alkylamino-C₁-C₆-alkoxy, C₁-C₆-alkylamino-C₁-C₆-alkoxy-C₁-C₆-alkoxy, halosulfonyl,
 5 optionally substituted 4-6 membered heterocyclyl-carbonylalkyl, C₁-4-alkoxycarbonylamino-C₁-6-alkyl,



, optionally substituted C₃-6-cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted
 10 phenyl-C₁-6-alkylenyl, optionally substituted 4-6 membered heterocyclyl-C₁-C₆-alkylenyl, 4-6 membered heterocyclyl-C₂-C₆-alkenylenyl, C₁-4-alkyl, cyano, C₁-4-hydroxyalkyl, nitro and C₁-4-haloalkyl;

wherein R³ is phenyl substituted with one or more
 15 substituents independently selected from halo, -OR⁷, -SR⁷, -CO₂R⁷, -CONR⁷R⁷, -COR⁷, -NR⁷R⁷, -SO₂NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, C₃-6-cycloalkyl, optionally substituted 5-6 membered heterocyclyl, optionally substituted phenyl, C₁-4-alkyl, C₁-4-aminoalkyl, cyano, C₁-4-hydroxyalkyl, nitro
 20 and C₁-4-haloalkyl;

wherein R^{4a} is C₂-4-alkylenyl where one of the CH₂ groups may be replaced with an oxygen atom or -NH-, wherein R^{4a} is optionally substituted with hydroxy;

wherein R⁵ is selected from H and C₁-C₂-alkyl;

25 wherein R^{5a} is selected from H and C₁-C₂-alkyl; and

wherein R⁷ is selected from H, C₁-4-alkyl, optionally substituted phenyl, optionally substituted phenyl-C₁-4-alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C₁-4-alkyl, optionally substituted C₃-C₆ cycloalkyl, C₁-2-alkylamino-C₁-4-alkyl and C₁-2-haloalkyl;
 30


wherein R^e and R^f are independently selected from H and C₁-2-haloalkyl; and

Sch
bi

404555 "0100"

wherein R^g is selected from H, C₁₋₆-alkyl, optionally substituted phenyl-C₁₋₆-alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C₁-C₆-alkyl, C₁₋₄-alkoxy-C₁₋₄-alkyl and C₁₋₄-alkoxy-C₁₋₄-alkoxy-C₁₋₄-alkyl, and pharmaceutically acceptable derivatives thereof.

3. Compound of Claim 2 wherein A is selected from



pyridyl and pyrimidinyl; wherein X is H ; wherein
10 Y is $-\text{NH}-\text{CH}_2-$; wherein R^1 is one or more substituents
independently selected from H, halo, hydroxy, C_{1-2} -alkoxy,
 C_{1-2} -haloalkoxy, amino, C_{1-2} -alkylamino, optionally
substituted 5-6 membered heterocyclyl- C_{1-2} -alkylamino,
aminosulfonyl, C_{3-6} -cycloalkyl, optionally substituted 5-6
15 membered heterocyclyl, optionally substituted phenyl, C_{1-4} -
alkyl, cyano, C_{1-2} -hydroxyalkyl, C_{1-3} -carboxyalkyl, nitro, C_{2-3} -
alkenyl, C_{2-3} -alkynyl and C_{1-2} -haloalkyl; wherein R^2 is
unsubstituted or substituted and selected from phenyl,
naphthyl, indanyl, indenyl and tetrahydronaphthyl,
20 substituted or unsubstituted 5-6 membered heteroaryl, C_{3-6} -
cycloalkyl, and substituted or unsubstituted 9-10 membered
bicyclic or 13-14 membered tricyclic heterocyclyl; wherein
substituted R^2 is substituted with one or more substituents
independently selected from halo, C_{1-4} -alkyl, optionally
25 substituted C_{3-6} -cycloalkyl, optionally substituted phenyl,
optionally substituted phenyl- C_{1-4} -alkylenyl, C_{1-2} -
haloalkoxy, optionally substituted phenyloxy, optionally
substituted 5-6 membered heterocyclyl- C_{1-4} -alkylenyl,
optionally substituted 5-6 membered heterocyclyl- C_{2-4} -
30 alkenylenyl, optionally substituted 5-6 membered
heterocyclyl, optionally substituted 5-6 membered
heterocyclyloxy, optionally substituted 5-6 membered

$$\begin{array}{c} R^e \quad R^f \\ \diagdown \quad \diagup \\ O \quad R^g \end{array}$$

4. Compound of Claim 3 wherein A is pyridyl; wherein R¹ is one or more substituents independently selected from H, chloro, and fluoro; wherein R² is selected from phenyl, tetrahydronaphthyl, indanyl, naphthyl, imidazolyl, oxazolyl, furyl, pyrrolyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, cyclohexyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3,4-tetrahydro-quinolyl, 2,3-dihydro-1H-indolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, and benzo[1,4]dioxanyl; wherein substituted R² is substituted with one or more substituents independently selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, methylpiperazinylmethyl, morpholinylethyl, methylpiperazinylpropyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidinylmethyl, morpholinylpropyl, methylpiperidinylmethyl, piperidinylethyl, piperidinylpropyl, pyrrolidinylpropyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, piperidinylmethylcarbonyl, methylpiperazinylcarbonylethyl, methoxycarbonyl, 3-ethoxycarbonyl-2-methyl-fur-5-yl, methylpiperazinyl, methylpiperidyl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, trifluoromethoxy, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl,

Sub
B1

FOUO 04003

Sub
B1

dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, 1-
methylpiperidin-4-yloxy, isopropoxy, methoxy and ethoxy; and
wherein R³ is phenyl substituted with one or more
substituents selected from chloro, fluoro, bromo, hydroxy,
5 methoxy, ethoxy, amino, dimethylamino, diethylamino, 1-
methylpiperidinylmethoxy, aminosulfonyl, cyclohexyl,
dimethylaminopropynyl, dimethylaminoethoxy, 3-(4-
morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy,
optionally substituted piperidinyl, morpholinyl, optionally
10 substituted piperazinyl, optionally substituted phenyl,
methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl,
nitro and trifluoromethyl; and pharmaceutically acceptable
derivatives thereof.

15 5. Compound of Claim 1 and pharmaceutically acceptable
derivatives thereof selected from

N-(4-Chlorophenyl){3-[benzylamino](2-pyridyl)}carboxamide;
N-(4-Chlorophenyl)(3-{{(4-nitrophenyl)methyl}amino}(2-
20 pyridyl))-carboxamide;
(2-[[{(4-methoxyphenyl)methyl}amino](2-pyridyl)))-N-(3-fluoro-
4-methylphenyl)carboxamide;
(6-Chloro-2-[[{(4-methoxyphenyl)methyl}amino](3-pyridyl)))-N-
(3-fluoro-4-methylphenyl)carboxamide;
25 (6-Chloro-2-[[{(4-methoxyphenyl)methyl}amino](3-pyridyl)))-N-
(3-fluoro-4-methylphenyl)carboxamide ;
(6-Chloro-2-[[{(4-methoxyphenyl)methyl}amino](3-pyridyl)))-N-
(3-fluoro-4-methylphenyl)carboxamide, hydrochloride;
(6-Chloro-2-{{(4-methoxyphenyl)methyl}amino}(3-pyridyl)))-N-
30 (4-chlorophenyl)carboxamide;
2-(3-Fluoro-benzylamino)-N-(4-phenoxy-phenyl)-nicotinamide;
N-(4-Phenoxyphenyl)[2-({[3-
(trifluoromethyl)phenyl]methyl}amino)(3-
pyridyl)]formamide;

1004525-01002

- 2-[[(4-Fluorophenyl)methyl]amino] (3-pyridyl)) -N- (4-
phenoxyphenyl) formamide;
N- (4-Phenoxyphenyl) [2- ((4-
 (trifluoromethyl)phenyl)methyl)amino] (3-
5 pyridyl)] formamide;
2-[[(2-Bromophenyl)methyl]amino] (3-pyridyl)) -N- (4-
phenoxyphenyl) formamide;
N- (4-Phenoxyphenyl) [2- ((4-
 (trifluoromethoxy)phenyl)methyl)amino] (3-
10 pyridyl)] formamide;
2-[[(2,3-Difluorophenyl)methyl]amino] (3-pyridyl)) -N- (4-
phenoxyphenyl) formamide;
N- (4-Chlorophenyl) (2-[[(4-cyanophenyl)methyl]amino] (3-
pyridyl)) carboxamide;
15 N- (4-Chlorophenyl) (2-[[(2-cyanophenyl)methyl]amino] (3-
pyridyl)) carboxamide;
N- (4-sec-butylphenyl) -2-[[(4-fluorobenzyl)amino]nicotinamide;
N- (4-tert-Butylphenyl) -2-[[(4-
fluorobenzyl)amino]nicotinamide;
20 N- (4-Isopropyl-phenyl) -2- (3-methoxy-benzylamino) -
nicotinamide;
2-[[(4-Fluorophenyl)methyl]amino] (3-pyridyl)) -N- [4-
 (methylethyl)phenyl]carboxamide;
2-[[(4-Fluorophenyl)methyl]amino] (3-pyridyl)) -N- [3-
25 (trifluoromethyl)phenyl]carboxamide;
2-[[(3,4-Dimethoxyphenyl)methyl]amino] (3-pyridyl)) -N- [3-
 (trifluoromethyl)phenyl]carboxamide;
2- [Benzylamino] (3-pyridyl)) -N- [3- (trifluoromethyl)phenyl] -
carboxamide;
30 2-[[(3-Chlorophenyl)methyl]amino] (3-pyridyl)) -N- [3-
 (trifluoromethyl)phenyl]carboxamide;
2-[[(4-Bromophenyl)methyl]amino] (3-pyridyl)) -N- [3-
 (trifluoromethyl)phenyl]carboxamide;

20250323 0400

- 2-(((4-Chlorophenyl)methyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;
- (2-(((2,4-Difluorophenyl)methyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;
- 5 (2-(((4-Fluorophenyl)ethyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;
- (2-(((3,4-Difluorophenyl)methyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;
- (2-(((2,3-Difluorophenyl)methyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;
- 10 (2-(((2-Fluorophenyl)methyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;
- (2-(((2,6-Difluorophenyl)methyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;
- 15 (2-(((3-Bromophenyl)methyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;
- (2-(((4-Fluorophenyl)methyl)amino)(3-pyridyl))-N-[4-(trifluoromethyl)phenyl]carboxamide;
- N-[3-[3-(Dimethylamino)propyl]-5-(trifluoromethyl)phenyl](2-
20 {[(4-fluorophenyl)methyl]amino)(3-pyridyl))carboxamide;
- {2-[(3-[3-(Dimethylamino)propyl]-4-fluorophenyl)methyl]amino}(3-pyridyl))-N-[4-(tert-butyl)phenyl]carboxamide;
- {2-[(3-[3-(Dimethylamino)propyl]-4-
25 fluorophenyl)methyl]amino}(3-pyridyl))-N-[4-(trifluoromethyl)phenyl]carboxamide;
- {2-[(3-[3-(Dimethylamino)propyl]-4-fluorophenyl)methyl]amino}(3-pyridyl))-N-(4-bromo-2-fluorophenyl)carboxamide;
- 30 2-[(4-Fluorobenzyl)amino]-N-[4-tert-butyl-3-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]nicotinamide;
- [2-(((4-Fluoro-3-(3-morpholin-4-ylprop-1-ynyl)phenyl)methyl)amino)(3-pyridyl))-N-[3-(trifluoromethyl)phenyl]carboxamide;


404556-0100

- {2-[(2H-Benzo[d]1,3-dioxol-5-ylmethyl)amino](3-pyridyl)}-N-(4-phenoxyphenyl)carboxamide;
- 2-(4-Fluoro-benzylamino)-N-[3-(2-pyrrolidin-1-yl-ethoxy)-4-trifluoromethyl-phenyl]-nicotinamide;
- 5 2-(4-Fluoro-benzylamino)-N-[3-(1-Boc-pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide;
- N-[4-tert-Butyl-3-(1-Boc-piperidin-4-ylmethoxy)-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;
- N-[3,3-Dimethyl-1-(1-methyl-piperidin-4-yl)-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;
- 10 N-[1-(2-Dimethylamino-acetyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;
- N-[1-(1-Boc-piperidin-4-yl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;
- 15 N-[3,3-Dimethyl-1-(2-Boc-amino-acetyl)-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;
- 2-(4-Fluoro-benzylamino)-N-(2-Boc-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-nicotinamide;
- N-[3-(1-Boc-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;
- 20 N-[4-tert-Butyl-3-(1-Boc-pyrrolidin-2-ylmethoxy)-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;
- N-(4-Acetyl-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-2-(4-fluoro-benzylamino)-nicotinamide;
- 25 2-(4-Fluoro-benzylamino)-N-[3-(1-Boc-piperidin-4-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide.;
- 2-(4-Fluoro-benzylamino)-N-[3-(pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide;
- 2-(4-Fluoro-benzylamino)-N-[3-(pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;
- 30 N-[4-tert-Butyl-3-(piperidin-4-ylmethoxy)-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;
- N-[4-tert-Butyl-3-(pyrrolidin-2-ylmethoxy)-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;

2007-03-23 10:01

- N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(4-fluoro-benzylamino)-nicotinamide;
 N-[1-(2-Amino-acetyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;
 5 N-(3,3-Dimethyl-1-piperidin-4-yl-2,3-dihydro-1H-indol-6-yl)-2-(4-fluoro-benzylamino)-nicotinamide;
 2-(4-Fluoro-benzylamino)-N-[3-(piperidin-4-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;
 N-(2,2-Dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-2-(4-fluoro-benzylamino)-nicotinamide;
 10 2-(4-Fluoro-benzylamino)-N-[3-(1-methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;
 N-[3,3-Dimethyl-1-(1-methyl-piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-
 15 nicotinamide;
 2-(4-Fluoro-benzylamino)-N-{4-[1-methyl-1-(1-methyl-piperidin-4-yl)-ethyl]-phenyl}-nicotinamide;
 N-(4,4-Dimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-2-(4-fluoro-benzylamino)-nicotinamide; and
 20 3-Benzo[1,3]dioxol-5-yl-3-[3-(4-pentafluoroethyl-phenylcarbamoyl)-pyridin-2-ylamino]-propionic acid.

6. Compound of Claim 1 of formula II'



II'

wherein each of A³ and A⁴ is independently CH or N, provided
 at least one of A³ and A⁴ is N;
 wherein n is 1-2;

wherein R¹ is one or more substituents independently
selected from H, chloro, fluoro, bromo, hydroxy, methoxy,
ethoxy, trifluoromethoxy, oxo, amino, dimethylamino,
aminosulfonyl, carboxymethyl, cyclopropyl, optionally
5 substituted phenyl, methyl, ethyl, propyl, cyano,
hydroxymethyl, nitro, propenyl, propynyl,
morpholinylethylamino, trifluoromethyl and unsubstituted
or substituted heteroaryl selected from thienyl, furanyl,
pyridyl, imidazolyl and pyrazolyl;

10 wherein R² is selected from a substituted or unsubstituted
ring selected from phenyl, tetrahydronaphthyl, indanyl,
benzodioxolyl, indenyl, naphthyl, isoxazolyl, pyrazolyl,
thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl,
pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-
15 isoquinolyl, 1,2,3,4-tetrahydro-quinolyl, isoquinolyl,
quinolyl, indolyl, isoindolyl, 2,3-dihydro-1H-indolyl,
naphthyridinyl, quinoxalinyl, 2,3,4,4a,9,9a-hexahydro-1H-
3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-
a]isoquinolyl, indazolyl, 2,1,3-benzothiadiazolyl, 3,4-
20 dihydro-2H-benzo[1,4]oxazinyl, benzodioxanyl,
benzothienyl, benzofuryl, benzimidazolyl, benzoxazolyl
and benzthiazolyl;

wherein substituted R² is substituted with one or more
substituents independently selected from bromo,
25 chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl,
Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-
methylpiperazinylsulfonyl, cyclohexyl, phenyl,
phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-
ylmethyl, 1-methylpiperazin-4-ylpropyl,
30 morpholinylpropyl, piperidin-1-ylmethyl, 1-
methylpiperidin-4-ylmethyl, 2-methyl-2-(1-
methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-
morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl,
1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-

Sub
Bl

200709290004


piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4-methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl, aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3-ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methylpyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; and

wherein R⁸ is one or more substituents independently selected from H, chloro, fluoro, bromo, hydroxy, methoxy,

ethoxy, -O-CH₂-O-, trifluoromethoxy, 1-methylpiperidinylmethoxy, dimethylaminoethoxy, amino, dimethylamino, dimethylaminopropyl, diethylamino, aminosulfonyl, cyclohexyl, dimethylaminopropynyl, 3-(4-morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy, 3-(4-morpholinyl)propylamino, optionally substituted piperidinyl, morpholinyl, optionally substituted piperazinyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl, nitro and trifluoromethyl;

provided R² is not 3-trifluoromethylphenyl when A³ is N, when A⁴ is CH, when n is 1, when R¹ is H and R⁸ is 4-hydroxy, 3-hydroxy or H; further provided R² is not 2-chloro-3-pyridyl when A³ is N, when A⁴ is CH, when n is 1, when R¹ is H and R⁸ is H or 4-methoxy; and further provided R² is not 2-methoxyphenyl when A³ is N, when A⁴ is CH, when n is 1, when R¹ is H and R⁸ is H.

7. Compound of Claim 1 of Formula III



III

wherein R¹ is one or more substituents independently selected from


- H,
- halo,
- hydroxy,
- amino,
- C₁₋₆-alkyl,
- C₁₋₆-haloalkyl,

C₁₋₆-alkoxy,
C₁₋₂-alkylamino,
aminosulfonyl,
C₃₋₆-cycloalkyl,
cyano,
oxo,
C₁₋₂-hydroxyalkyl,
nitro,
C₂₋₃-alkenyl,
C₂₋₃-alkynyl,
C₁₋₆-haloalkoxy,
C₁₋₆-carboxyalkyl,
5-6-membered heterocyclyl-C₁₋₆-alkylamino,
unsubstituted or substituted phenyl and
unsubstituted or substituted 5-6 membered
heterocyclyl;
wherein R² is selected from unsubstituted or substituted
phenyl, and
9-10 membered bicyclic and 13-14 membered
tricyclic unsaturated or partially
unsaturated heterocyclyl,
wherein substituted R² is optionally substituted with one or
more substituents selected from halo, C₁₋₆-alkyl,
optionally substituted C₃₋₆-cycloalkyl, optionally
substituted phenyl, optionally substituted phenyl-C₁₋₄-
C₄-alkyl, C₁₋₂-haloalkoxy, optionally substituted
phenyloxy, optionally substituted 4-6 membered
heterocyclyl-C₁₋₄-alkyl, optionally substituted 4-6
membered heterocyclyl-C₂₋₄-alkenyl, optionally
substituted 5-6 membered heterocyclyl, optionally
substituted 4-6 membered heterocycliloxy, optionally
substituted 4-6 membered heterocyclyl-C₁₋₄-alkoxy,
optionally substituted 5-6 membered
heterocyclylsulfonyl, optionally substituted 5-6

Sub

[illegible]

5 membered heterocyclylamino, optionally substituted 5-6
 membered heterocyclylcarbonyl, optionally substituted
 5-6 membered heterocyclylcarbonyl-C₁₋₄-alkyl,
 optionally substituted 5-6 membered heterocyclyl-C₁₋₄-
 10 alkylcarbonyl, C₁₋₄-haloalkyl, C₁₋₄-aminoalkyl, nitro,
 amino, hydroxy, oxo, cyano, aminosulfonyl, C₁₋₂-
 alkylsulfonyl, halosulfonyl, C₁₋₄-alkylcarbonyl, amino-
 C₁₋₄-alkylcarbonyl, C₁₋₄-alkylamino-C₁₋₄-alkylcarbonyl,
 C₁₋₃-alkylamino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkoxy,
 15 C₁₋₃-alkylamino-C₁₋₃-alkoxy-C₁₋₃-alkoxy, C₁₋₄-
 alkoxycarbonyl, C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkyl, C₁-



wherein R^e and R^f are independently selected from H and C₁₋₂-
 haloalkyl;

15 wherein R⁷ is selected from H, C₁₋₃-alkyl, optionally
 substituted phenyl-C₁₋₃-alkyl, 4-6 membered
 heterocyclyl, and optionally substituted 4-6 membered
 heterocyclyl-C₁-C₃-alkyl;

wherein R⁹ is selected from H, C₁₋₃-alkyl, optionally
 20 substituted phenyl-C₁₋₃-alkyl, 4-6 membered
 heterocyclyl, and optionally substituted 4-6 membered
 heterocyclyl-C₁-C₃-alkyl, C₁₋₃-alkoxy-C₁₋₂-alkyl and C₁₋₃-
 alkoxy-C₁₋₃-alkoxy-C₁₋₃-alkyl; and

wherein R⁸ is one or more substituents independently
 25 selected from H, halo, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-
 haloalkyl, C₁₋₆-alkoxy, C₁₋₆-haloalkoxy, C₁₋₆-aminoalkyl, C₁-
 6-hydroxyalkyl, optionally substituted phenyl, optionally
 substituted heterocyclyl, optionally substituted
 heterocyclyl-C₁₋₆-alkoxy, aminosulfonyl, C₃₋₆-cycloalkyl,
 30 C₁₋₆-alkylamino, C₁₋₆-alkylamino-C₁₋₆-alkyl, optionally
 substituted heterocyclyl-C₁₋₆-alkylamino, optionally
 substituted heterocyclyl-C₁₋₆-alkyl, C₁₋₆-alkylamino-C₂₋₄-
 alkynyl, C₁₋₆-alkylamino-C₁₋₆-alkoxy, C₁₋₆-alkylamino-C₁₋₆-

Sub
 Bl

20070929

alkoxy-C₁₋₆-alkoxy, and optionally substituted heterocyclyl-C₂₋₄-alkynyl; and pharmaceutically acceptable isomers and derivatives thereof;

5 provided R² is not 3-trifluoromethylphenyl when R¹ is H and R⁸ is 4-hydroxy, 3-hydroxy or H; and further provided R² is not 2-methoxyphenyl when R¹ is H and R⁸ is H.

Sub
bl

8. Compound of Claim 7 wherein R¹ is selected from H,
10 chloro, fluoro, bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl, morpholinylethylamino, propynyl, unsubstituted or
15 substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl, furanyl, pyridyl, imidazolyl, and pyrazolyl; wherein R² is selected from phenyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3,4-tetrahydro-
20 quinolyl, 2,3-dihydro-1H-indolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, and benzo[1,4]dioxanyl, where R² is unsubstituted or substituted with one or more
25 substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, 30 morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-

E0070"929400F

[illegible]

Sub
Bl

5 aminosulfonyl, cyclohexyl, dimethylaminopropynyl, 3-(4-morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy, 3-(4-morpholinyl)propylamino, optionally substituted piperidinyl, morpholinyl, optionally substituted piperazinyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl and trifluoromethyl;
and pharmaceutically acceptable derivatives thereof.

- 10 9. Compound of Claim 8 wherein R¹ is selected from H, chloro or fluoro;
wherein R² is selected from
- 15 1,2,3,4-tetrahydro-isoquinolyl optionally substituted with one or more substituents selected from methyl, and Boc,
- 20 1,2,3,4-tetrahydro-quinolyl optionally substituted with one or more substituents selected from methyl, Boc and oxo,
- 25 2,3-dihydro-1H-indolyl optionally substituted with one or more substituents selected from methyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-yl, piperidin-4-yl, 1-methyl-piperidin-4-ylmethyl, 1-methyl-piperidin-4-yl, dimethylaminomethylcarbonyl, aminomethylcarbonyl, methylcarbonyl, pyrrolidin-2-ylmethyl, and 1-Boc-pyrrolidin-2-ylmethyl, and
- 30 3,4-dihydro-2H-benzo[1,4]oxazinyl optionally substituted with one or more substituents selected from methyl, and methylcarbonyl; and
- wherein R⁸ is one or more substituents independently selected from H, chloro, fluoro, bromo, cyano, methoxy, -O-CH₂-O-, amino, trifluoromethyl, trifluoromethoxy, 3-(4-morpholinyl)propyn-1-yl, dimethylaminopropyl, and 3-(4-morpholinyl)propylamino;

and pharmaceutically acceptable derivatives thereof.

10. Compound of Claim 8 wherein R¹ is selected from H, chloro or fluoro;
- 5 wherein R² is selected from phenyl optionally substituted with one or more substituents selected from bromo, chloro, fluoro, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl); methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, dimethylaminopropyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-1-ylethoxy, 1-methyl-pyrrol-2-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, and 1-methylpiperdin-4-yloxy;
- 15
- 20
- 25
- 30 and wherein R⁸ is one or more substituents independently selected from H, chloro, fluoro, bromo, cyano, methoxy, -O-CH₂-O-, amino, trifluoromethyl, trifluoromethoxy, 3-(4-morpholinyl)propyn-1-yl, dimethylaminopropyl, and 3-(4-morpholinyl)propylamino;

Sub
B1
COFFEE

and pharmaceutically acceptable derivatives thereof.

Sub
B1
5 11. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound as in any of Claims 1-10.

10 12. A method of treating cancer in a subject, said method comprising administering an effective amount of a compound as in any of Claims 1-10.

15 13. The method of Claim 12 comprising a combination with a compound selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and miscellaneous agents.

20 14. A method of treating angiogenesis in a subject, said method comprising administering an effective amount of a compound as in any of Claims 1-10.

25 15. A compound as in any of Claims 1-10 for use in a method of therapeutic treatment for the human or animal body.

Sub
B1
25 16. A method of treating KDR-related disorders in a mammal, said method comprising administering an effective amount of a compound as in any of Claims 1-10.

30 17. A method of treating proliferation-related disorders in a mammal, said method comprising administering an effective amount of a compound as in any of Claims 1-10.

add
B1